Subscribe
Carla Ji-Eun Kim and Deborah Sterling of Sterne Kessler
2 January 2025FeaturesAmericasCarla Ji-Eun Kim & Deborah Sterling

Outlook for 2025: how Trump and the USPTO will affect life sciences IP

Key developments for the industry this year include a more pro-patent administration and USPTO changes, say Carla Ji-Eun Kim and Deborah Sterling of Sterne Kessler.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
CREATES Act unfairly tips the scales to generics
19 December 2024   The act’s one-sided provisions and its disproportionate remedies cannot pass constitutional muster, argues John Cox of Barnes & Thornburg.
Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024   As President-elect Donald Trump prepares for his second term, the life sciences industry is calling for predictability, finds Marisa Woutersen.
Americas
President Trump 2.0: Five major areas to watch
7 November 2024   As Donald Trump celebrates a second term, LSIPR looks at how key IP areas could be affected ahead of his return to the Oval Office.


Editor's picks

Trouble at the USPTO—Part II: Bracing for impact
Americas
Trouble at the USPTO—Part II: Bracing for impact
13 March 2025

Editor's picks

Americas
Trouble at the USPTO—Part II: Bracing for impact
13 March 2025
Americas
Trouble at the USPTO—Part I: Why government cutbacks are making everyone nervous
6 March 2025
Americas
‘Lift as you climb’: Abbott, BMS, Hitachi, LEGO Group counsels explore ‘empowerment’
6 March 2025
Careers
Jones Day adds experienced patent litigators from Weil
4 March 2025
Americas
LSPN finalists revealed for first-ever US awards
3 March 2025
Europe
‘It’s business as usual’: ERS Genomics enjoys new EPO patent after CRISPR gambit pays off
27 February 2025

More on this story

Americas
CREATES Act unfairly tips the scales to generics
19 December 2024   The act’s one-sided provisions and its disproportionate remedies cannot pass constitutional muster, argues John Cox of Barnes & Thornburg.
Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024   As President-elect Donald Trump prepares for his second term, the life sciences industry is calling for predictability, finds Marisa Woutersen.
Americas
President Trump 2.0: Five major areas to watch
7 November 2024   As Donald Trump celebrates a second term, LSIPR looks at how key IP areas could be affected ahead of his return to the Oval Office.

More on this story

Americas
CREATES Act unfairly tips the scales to generics
19 December 2024   The act’s one-sided provisions and its disproportionate remedies cannot pass constitutional muster, argues John Cox of Barnes & Thornburg.
Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024   As President-elect Donald Trump prepares for his second term, the life sciences industry is calling for predictability, finds Marisa Woutersen.
Americas
President Trump 2.0: Five major areas to watch
7 November 2024   As Donald Trump celebrates a second term, LSIPR looks at how key IP areas could be affected ahead of his return to the Oval Office.

More features

Patent cliff: 5 blockbusters running out of road
Novartis and MSN feud intensifies after Fed Circ denies rehearing
EU court signals tough stance on ‘pay-for-delay’ pharma deals
Panitch Schwarze hires experienced ex-USPTO examiner
Fed Circ affirms generic’s litigation costs of $12m are tax-deductible
Genmab fights claim over 'secrets theft' behind $1.8bn takeover
Interpreting the SPC manufacturing waiver: EU courts diverge
European court upholds 10x patent after Nanostring appealed injunction